Johnson & Johnson is recalling more musty-smelling Tylenol. The new recall from Johnson & Johnson’s McNeil Consumer Healthcare unit involves around 34,000 150-count bottles of Tylenol 8 Hour Extended Release Caplets.
The latest <"https://www.yourlawyer.com/topics/overview/Tylenol-Liver-Damage-Injury-Lawsuit-Lawyer">Tylenol recall was prompted by a “small number” of consumer complaints about a musty smell, a McNeil statement said. The company said the musty smell was the result of trace amounts of chemicals called 2,4,6-tribromoanisole (TBA) and 2,4,6-trichloroanisole (TCA). The company says TBA is the result of a chemical applied to wood pallets that transport and store packaging materials. TBA has been behind other recalls of musty-smelling Tylenol in the past. However, according to a Dow Jones Newswires report, TCA has not been cited by Johnson & Johnson in prior recalls.
Johnson & Johnson also added 10 product lots (more than 717,000 bottles) of various Tylenol, Benadryl and Sudafed products to a recall of medicines at the wholesale level first announced in January. According to the company, the recall is a precautionary measure because a review of past manufacturing records found cases where equipment cleaning procedures were insufficient, or cleaning wasn’t adequately documented. Because it is a wholesale level recall, no consumer action is required.
According to a report in The New York Times, the products involved in these recalls were made at McNeilâ€™s Fort Washington, Pennsylvania plant. As we reported earlier this month, that facility, which was temporarily closed last year because of quality issues, is named in a consent decree and won’t be able to reopen until the U.S. Food & Drug Administration (FDA) is assured that it meets quality standards. It is one of three Johnson & Johnson plants that would be subject to greater federal oversight under the consent decree.
This is just the latest in a string of recalls that have cost Johnson & Johnson more than $900 million in sales over the past year. The tally includes 20 recalls issued by its McNeil Consumer Healthcare division that have involved upwards of 200 million bottles -including childrenâ€™s formulations â€“ of Tylenol, Motrin and other over-the-counter drugs. Last month, the companyâ€™s Ortho-McNeil-Janssen Pharmaceuticals division recalled prefilled Invega Sustenna syringe. Just last week, Ethicon recalled a number of surgical drainage products because of sterility issues. Other Johnson & Johnson recalls have involved two DePuy hip replacement implants sold by its DePuy Orthopaedics unit, insulin pump cartidges made by its Animas unit, 1-Day Acuvue TruEye contact lenses, and Simponi injection pens.